P H Tan1, A K Bharath. 1. Oxford University, John Radcliffe Hospital, Nuffield Department of Surgery, Oxford, OX3 9DU, UK. peng.tan@nds.ox.ac.uk
Abstract
BACKGROUND: The discovery of indoleamine 2,3-dioxygenase (IDO) as a modulator for the maintenance of fetomaternal immuno-privileged state has been heralded as a significant step in further defining the role of IDO in immunobiology. IDO is an IFN-inducible, intracellular enzyme that catalyzes the initial and rate-limiting step in the degradation of the essential amino acid, tryptophan. It has been suggested that IDO has the capacity to regulate the immune system via two discrete mechanisms; firstly the deprivation of tryptophan, which is essential for T cell proliferation and via the cytotoxic effects of tryptophan metabolites on T(H)1 cell survival. METHODS: The sources of information used to prepare the paper are published work on Pubmed/Medline. In this review, we examine the therapeutic role of modulating IDO activity a variety of disease states including tumour tolerance, chronic infection, transplant rejection, autoimmunity and asthma. We propose that IDO represents a novel therapeutic target for the treatment of these diseases. We also explore the diverse strategies which are being employed, either to augment or to inhibit IDO activity in order to modify various disease processes. The limitations associated with these strategies are also scrutinized.
BACKGROUND: The discovery of indoleamine 2,3-dioxygenase (IDO) as a modulator for the maintenance of fetomaternal immuno-privileged state has been heralded as a significant step in further defining the role of IDO in immunobiology. IDO is an IFN-inducible, intracellular enzyme that catalyzes the initial and rate-limiting step in the degradation of the essential amino acid, tryptophan. It has been suggested that IDO has the capacity to regulate the immune system via two discrete mechanisms; firstly the deprivation of tryptophan, which is essential for T cell proliferation and via the cytotoxic effects of tryptophan metabolites on T(H)1 cell survival. METHODS: The sources of information used to prepare the paper are published work on Pubmed/Medline. In this review, we examine the therapeutic role of modulating IDO activity a variety of disease states including tumour tolerance, chronic infection, transplant rejection, autoimmunity and asthma. We propose that IDO represents a novel therapeutic target for the treatment of these diseases. We also explore the diverse strategies which are being employed, either to augment or to inhibit IDO activity in order to modify various disease processes. The limitations associated with these strategies are also scrutinized.
Authors: Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz Journal: J Neurochem Date: 2010-03-17 Impact factor: 5.372
Authors: Luis Munoz-Erazo; Ricardo Natoli; Jan Marie Provis; Michelle Catherine Madigan; Nicholas Jonathan Cole King Journal: Mol Vis Date: 2012-03-27 Impact factor: 2.367
Authors: Myoung Woo Lee; Dae Seong Kim; Somi Ryu; In Keun Jang; Hye Jin Kim; Jin Mo Yang; Doo-Hoon Lee; Soo Hyun Lee; Meong Hi Son; Hee Won Cheuh; Hye Lim Jung; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo Journal: Biomed Res Int Date: 2013-06-04 Impact factor: 3.411
Authors: Wojciech Dabrowski; Tomasz Kocki; Jacek Pilat; Jolanta Parada-Turska; Manu L N G Malbrain Journal: Inflammation Date: 2014-02 Impact factor: 4.092